Shanghai Junshi Biosciences Co. Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of … Read more
Shanghai Junshi Biosciences Co. Ltd - Asset Resilience Ratio
Shanghai Junshi Biosciences Co. Ltd (SHJBF) has an Asset Resilience Ratio of 4.28% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Shanghai Junshi Biosciences Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Junshi Biosciences Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $500.57 Million | 4.28% |
| Total Liquid Assets | $500.57 Million | 4.28% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Junshi Biosciences Co. Ltd maintains only 4.28% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Junshi Biosciences Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Junshi Biosciences Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Shanghai Junshi Biosciences Co. Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Junshi Biosciences Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.99% | $430.51 Million | $10.80 Billion | +3.99pp |
| 2023-12-31 | 0.00% | $284.00 | $11.36 Billion | -9.56pp |
| 2022-12-31 | 9.56% | $1.20 Billion | $12.56 Billion | -1.58pp |
| 2021-12-31 | 11.15% | $1.23 Billion | $11.05 Billion | +11.15pp |
| 2020-12-31 | 0.00% | $17.00K | $8.01 Billion | 0.00pp |
| 2019-12-31 | 0.00% | $17.00K | $4.42 Billion | -0.13pp |
| 2018-12-31 | 0.13% | $5.52 Million | $4.26 Billion | -11.96pp |
| 2017-12-31 | 12.09% | $147.43 Million | $1.22 Billion | -20.42pp |
| 2016-12-31 | 32.50% | $373.47 Million | $1.15 Billion | -38.21pp |
| 2014-12-31 | 70.71% | $235.44 Million | $332.94 Million | -- |